Fiordaliza Toribio, MD
Internal Medicine · Tampa, FLNPI 1497796270
Payments from drug & device makers
Across 141 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$433
- Amgen$378
- Pfizer$337
- AbbVie$235
- Lilly USA, LLC$220
- Bayer$171
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,73997%
- Education$853%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 23 | $433 |
| Amgen(2 entities) | 19 | $378 |
| Pfizer | 17 | $337 |
| AbbVie(2 entities) | 12 | $235 |
| Lilly USA, LLC | 11 | $220 |
| Bayer | 7 | $171 |
| Xeris Pharmaceuticals, Inc. | 7 | $145 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $131 |
| GSK | 7 | $120 |
| Astellas Pharma US Inc | 2 | $105 |
| Novo Nordisk | 3 | $62 |
| Boehringer Ingelheim | 3 | $60 |
| Mylan Specialty L.p. | 2 | $48 |
| Biogen | 2 | $46 |
| Eisai Inc. | 2 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Johnson & Johnson | 2 | $36 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Novartis | 2 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $17 |
| Merck | 1 | $16 |
| Smith+Nephew | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
| Urovant Sciences Inc | 1 | $14 |
How this compares
$2,824 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 98 | $94,023 |
| TrulicityDulaglutide | 48 | $75,113 |
| JanuviaSitagliptin Phosphate | 53 | $68,873 |
| OzempicSemaglutide | 54 | $57,600 |
| XareltoRivaroxaban | 58 | $50,356 |
| JardianceEmpagliflozin | 28 | $48,040 |
| EliquisApixaban | 54 | $45,373 |
| MounjaroTirzepatide | 30 | $34,161 |
| FarxigaDapagliflozin Propanediol | 22 | $32,711 |
| SymbicortBudesonide/Formoterol Fumarate | 64 | $26,561 |
| TradjentaLinagliptin | 39 | $25,980 |
| VascepaIcosapent Ethyl | 31 | $25,083 |
| ProliaDenosumab | 12 | $21,176 |
| MyrbetriqMirabegron | 37 | $19,964 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $15,898 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $220 | $109,27578 claims |
| AbbVieLinzess, Namzaric | $235 | $101,825109 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $60 | $85,90187 claims |
| MerckJanuvia | $16 | $68,87353 claims |
| AstraZenecaFarxiga, Symbicort | $433 | $59,27286 claims |
| Novo NordiskOzempic | $62 | $57,60054 claims |
| Johnson & JohnsonXarelto | $36 | $50,35658 claims |
| PfizerEliquis | $337 | $45,37354 claims |
| AmgenProlia | $378 | $21,17612 claims |
| Astellas Pharma US IncMyrbetriq | $105 | $19,96437 claims |
| GSKBreo Ellipta | $120 | $13,19326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Tampa
- Jhanelle GrayTampa$20.8M
- Sady AlpizarTampa$13.5M
- Karon LociceroTampa$6.6M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.